2Hughes RAC, et al. Controlled trial of prednisolone in acute polyneuropathy. Lancet, 1978,2:750
3Sater RA, Rostami A. Treatment of Guillain-Barre.Syndrome with Intravenous Immunoglobulin. Neurology, 1998,51(Suppl 5)S9-S15
4The Dutch Guillain-Barre Study Group. Treatment of Guillain-Barre syndrome with high-dose immuneglobulins. combined with methylprednisolone: a pilot study. Ann Neurol, 1994,35:794-752
5Van der Meche FGA, Schnmitz PIM, the Dutch Guillain-Bare Study Group. A randomize trail comparing intravenous immune globulin and Plasma exchange in Gulillain-Barre syndrome. N Engl J Med, 1992,326:1123-1129
6McKhann GM, Griffin JW,Comblath DR, et al. Plasmapheresis and Guillain-Barre syndrome;analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol, 1988,23:347-353
7Winer JB, Hughes RAC, Osmond C.A prospective study of acute idiopathic neuropathy. I Clinical features and their prognostic value. J Neurol Neurosurg Psychiatty, 1988, 51:605-612
8HaaB A, Trabert W, Gressnich N, Schinrigk K. High-dose sterold therapy in Guillain-Barre syndrome. J Neuroimmunol, 1988; 20:305-308
9Guillain-Barre Syndrome Steroid Trial Grope. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome, Lancet, 1993:341-586-590
9Hughes RA,Wijdicks EF, Barohn R, et al. Practice parameter: im- munotherapy for Guillain-Barr6 syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology [ J]. Neurology, 2003,61 (6) : 736-740.
